Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase ; volume:8 ; number:1 ; day:13 ; month:12 ; year:2017 ; pages:1-14 ; date:12.2017
Nature Communications ; 8, Heft 1 (13.12.2017), 1-14, 12.2017
- Klassifikation
-
Biowissenschaften, Biologie
- Urheber
-
Reckel, Sina
Gehin, Charlotte
Tardivon, Delphine
Georgeon, Sandrine
Kükenshöner, Tim
Löhr, Frank
Koide, Akiko
Buchner, Lena
Panjkovich, Alejandro
Reynaud, Aline
Pinho, Sara
Gerig, Barbara
Svergun, Dmitri
Pojer, Florence
Güntert, Peter
Dötsch, Volker
Koide, Shohei
Gavin, Anne-Claude
Hantschel, Oliver
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-017-02313-6
- URN
-
urn:nbn:de:101:1-2019070801325469362869
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Reckel, Sina
- Gehin, Charlotte
- Tardivon, Delphine
- Georgeon, Sandrine
- Kükenshöner, Tim
- Löhr, Frank
- Koide, Akiko
- Buchner, Lena
- Panjkovich, Alejandro
- Reynaud, Aline
- Pinho, Sara
- Gerig, Barbara
- Svergun, Dmitri
- Pojer, Florence
- Güntert, Peter
- Dötsch, Volker
- Koide, Shohei
- Gavin, Anne-Claude
- Hantschel, Oliver
- SpringerLink (Online service)
Ähnliche Objekte (12)
Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
Bcr-Abl tyrosine kinase inhibitors- current status
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN
The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia
BCR/ABL positive thrombocythemia: a diagnostic dilemma
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
Bcr-Abl tyrosine kinase inhibitors- current status
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN
The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia
BCR/ABL positive thrombocythemia: a diagnostic dilemma
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
Bcr-Abl tyrosine kinase inhibitors- current status
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN
The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia
BCR/ABL positive thrombocythemia: a diagnostic dilemma
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis